CJC-1295 (no DAC): Research Roundup

CJC-1295 without DAC refers to a tetrasubstituted GHRH(1-29) analog — a synthetic peptide that mimics the first 29 amino acids of growth hormone releasing hormone with four amino acid substitutions designed to resist enzymatic degradation. In research catalogs it appears under multiple names: "mod GRF 1-29," "Modified GRF 1-29," "CJC-1295 no DAC," and variations thereof. It is not the same material as CJC-1295 with DAC, which adds a Drug Affinity Complex linker for albumin binding and dramatically extended half-life. Treating these as interchangeable — in either research design or material procurement — is a documented source of experimental error. This roundup summarizes the no-DAC analog's pharmacology, its relationship to ghrelin mimetics such as ipamorelin and GHRP-2, and the analytical standards required to confirm you have the correct peptide.

What the literature describes

Native GHRH is a 44-amino-acid hypothalamic peptide; its biologically active N-terminal fragment GHRH(1-29) stimulates GH release through pituitary GHRH receptors. Unmodified GHRH(1-29) has a short half-life due to rapid proteolytic cleavage. Tetrasubstituted analogs — including the peptide commonly sold as CJC-1295 no DAC — incorporate amino acid modifications (typically at positions 2, 8, 15, and 27 in the research literature tradition) intended to reduce degradation while preserving receptor activity.

Preclinical studies examine GH release patterns following GHRH analog administration in animal models. The no-DAC form produces shorter-duration GH elevation compared with the DAC-modified version, which binds serum albumin and extends circulating half-life in pharmacokinetic research. That pharmacokinetic distinction is fundamental: experiments designed around pulsatile GH dynamics may require different compounds than experiments examining sustained GH elevation, and conflating the two forms undermines both.

Human data for this specific tetrasubstituted analog are limited relative to approved GHRH pharmaceutical products. Research pharmacology exists in defined contexts, but the no-DAC analog did not achieve standalone regulatory approval. Catalog availability reflects research demand, not clinical validation.

In GH-axis research, GHRH analogs are frequently discussed alongside ghrelin receptor agonists. Ipamorelin stimulates GH through GHS-R with reported selectivity advantages over GHRP-6 and hexarelin. GHRP-2 serves as a classic reference secretagogue. Preclinical combination studies explore whether simultaneous GHRH receptor and GHS-R activation produces greater GH release than either pathway alone. These combinations appear in research discussions pairing mod GRF with ipamorelin or GHRP-class peptides — but published synergy data remain predominantly animal-based and protocol-specific.

Distinguishing no-DAC from DAC: why it matters

The chemical difference is not subtle. CJC-1295 with DAC includes a maleimidoproprionic acid linker that conjugates to albumin, adding mass and altering pharmacokinetics. The no-DAC form lacks this modification entirely. Mass spectrometry should show clearly different molecular weights. A vendor selling one form while providing COA data for the other — a failure mode we encounter in vetting — renders the documentation worse than useless because it creates false confidence.

HPLC chromatograms also differ between forms. Retention time, peak shape, and impurity profiles are not transferable. Purity percentage on a DAC product tells you nothing about a no-DAC vial. Per-batch, per-form analysis is mandatory.

Naming ambiguity compounds the problem. A product labeled simply "CJC-1295" without specifying DAC status requires immediate clarification. Default skepticism is appropriate: confirm identity before any laboratory use. Our guide to peptide identity testing details the MS and HPLC checks that resolve this ambiguity.

Research design considerations

The no-DAC analog's shorter activity profile relative to CJC-1295 with DAC makes it relevant for experiments probing pulsatile GH dynamics or requiring more discrete temporal control over GHRH receptor activation. Studies that inadvertently use the DAC form when the no-DAC profile is intended — or vice versa — produce results that cannot be compared against the intended literature baseline. Include MS identity confirmation as a documented pre-experiment step, not an afterthought.

Combination protocols involving mod GRF and ghrelin mimetics appear frequently in research discussions. Ipamorelin is the most common ghrelin-side partner in those discussions because of its selectivity profile, but GHRP-2 and hexarelin appear in older synergy literature with different hormonal side-effect contexts. When citing combination studies, match the secretagogue class used in the original publication rather than substituting analogs based on catalog availability.

Tetrasubstituted GHRH peptides are sensitive to enzymatic degradation in solution. Published stability data from synthesis-era material may not reflect the behavior of current catalog lots stored under unknown conditions. Evaluate solubility, clarity, and repeat HPLC or MS checks when material age or storage history is uncertain. Independent third-party retesting is appropriate when vendor COAs are dated or storage conditions were not controlled.

Important limitations

• Naming chaos. Vendor labels conflate DAC and no-DAC, use inconsistent abbreviations, and sometimes misapply "CJC-1295" to unrelated sequences. MS identity is the only reliable arbiter.
• Preclinical focus. Most GH release data come from animal models. Human pharmacology for this specific analog is sparse compared with approved GHRH products.
• Not a substitute for approved GHRH drugs. Research-grade mod GRF differs from pharmaceutical GHRH formulations in regulatory status, manufacturing standards, and documented impurity profiles.
• Combination assumptions. Pairing with ipamorelin or GHRP-2 reflects research interest, not validated universal protocols.
• No use directions. This page excludes dosing, administration routes, and reconstitution guidance.

Evaluating the material

Confirm the exact tetrasubstituted GHRH(1-29) sequence and the absence of DAC modification via mass spectrometry on the specific batch you hold. HPLC purity alone cannot prove you received the no-DAC analog rather than the DAC form or an unrelated peptide entirely.

A complete COA includes MS identity, HPLC with chromatogram, lot traceability, and independent lab attribution. Learn to evaluate these fields through COA literacy. Understand why both chromatographic and mass-based confirmation matter in HPLC vs. MS.

Compare your documentation against our vetting scorecards, which assess vendor transparency and batch-specific data quality across the secretagogue category — including GHRP-6, hexarelin, and related compounds where mislabeling rates are elevated.

Related literature in this series

The no-DAC GHRH analog pairs naturally with the DAC form roundup for pharmacokinetic comparison, and with ghrelin mimetic roundups on ipamorelin, GHRP-2, GHRP-6, and hexarelin for secretagogue class context. Select compounds based on published pathway biology and verified material identity.

Questions about the research literature? Use the discussion below — research framing only, no human-use instructions.